Favipiravir pharmacokinetics in COVID-19 patients with moderate to severe kidney dysfunction: Lessons learned for future use

There is limited information on favipiravir pharmacokinetics in critically ill patients and no studies on pharmacokinetics in patients with moderate and severe kidney dysfunction. The aim was to determine favipiravir pharmacokinetics (oral, 1,600 mg, q12h on day 1, then 600 mg, q12h for 4 days) in c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of clinical pharmacology and therapeutics 2024-08
Hauptverfasser: Sürmelioğlu, Nursel, Demirtürk, Esra, Ateş Ayhan, Nazire, Özel Yeşilyurt, Aysun, Bayrakçi, Sinem, Kaynak, Mustafa Sinan, Özyılmaz, Ezgi, Allegaert, Karel
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:There is limited information on favipiravir pharmacokinetics in critically ill patients and no studies on pharmacokinetics in patients with moderate and severe kidney dysfunction. The aim was to determine favipiravir pharmacokinetics (oral, 1,600 mg, q12h on day 1, then 600 mg, q12h for 4 days) in critically ill COVID-19 patients with kidney dysfunction and to compare those with observations reported in healthy adults. In a descriptive study, blood samples taken from patients meeting the relevant criteria (estimated glomerular filtration rate
ISSN:0946-1965
DOI:10.5414/CP204496